Home Featured Page 287

Featured

Latest

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Mydecine Innovations Group Announces Migration to NEO Exchange

COMPASS Pathways granted two US patents

PT236 – Dr. Carl Hart – Drugs: Honesty, Responsibility, and Logic

Psychedelic Synesthesia: Smell That Tune

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation...

Mindset Pharma Announces $5 Million Bought Deal Financing

MindMed Announces Inclusion in FTSE Russell Indexes

Psychedelic Bulletin: Australian Gov Earmarks $15m for Psychedelic Studies; Otsuka Licences...

Numinus Announces Closing of $40-Million Bought Deal Financing

Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Mydecine Innovations Group Announces Migration to NEO Exchange

COMPASS Pathways granted two US patents

PT236 – Dr. Carl Hart – Drugs: Honesty, Responsibility, and Logic

Psychedelic Synesthesia: Smell That Tune

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation...

Mindset Pharma Announces $5 Million Bought Deal Financing

MindMed Announces Inclusion in FTSE Russell Indexes

Psychedelic Bulletin: Australian Gov Earmarks $15m for Psychedelic Studies; Otsuka Licences...

Numinus Announces Closing of $40-Million Bought Deal Financing

Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY